Chugai Expands Gene Bridges License | GenomeWeb

NEW YORK (GenomeWeb News) – Gene Bridges said today that the Chugai Pharmaceutical has expanded a license for the company's recombination technology.

The Japanese pharmaceutical firm agreed to expand a commercial license for the Red/ET technology that the companies originally struck in 2005.

Patented in Japan as a "Novel DNA Cloning Method," the Red/ET technology is used for generating targeting vectors or modifying E. coli chromosomes. The methodology allows cloning, subcloning, and DNA modification at any position, Gene Bridges said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.